Ohio's bad flu season to get worse as 'super flu' spreads, state warns

Ohio is experiencing a worsening flu season driven by a new influenza A (H3N2) variant dubbed the “super flu,” with 1,911 flu-related hospitalizations reported for the week ending Jan. 3 (up 446 from the prior week) and one pediatric death in-state; nine pediatric deaths have been reported nationally. The state, among those with the highest CDC-measured activity, warns infections will likely peak in February and urges vaccination despite low uptake (U.S. adult vaccination ~45%; Ohio adults 41.3%; Ohio children ~37.5%); officials note vaccines reduce severity and hospitalizations even if they do not fully prevent infection.

Analysis

Market structure: The immediate winners are diagnostic/test makers (Abbott ABT, Quidel/Ortho QDEL), vaccine manufacturers with flu franchises (Pfizer PFE, Moderna MRNA, Sanofi SNY) and healthcare staffing providers (AMN). Hospitals (HCA) may see revenue lift from admissions but face margin compression from overtime and deferred elective procedures; insurers (UNH, CVS/ACO) face higher short-term claims. Consumer-facing travel and leisure (AAL, DAL, XLY-exposed names) are likely to underperform for 2–8 weeks as sick days and cancellations rise.

Risk assessment: Tail risks include a vaccine-escape mutation or policy shock (e.g., erroneous HHS guidance reducing pediatric vaccination) that could amplify spread — low probability but high impact on cyclicals and small caps. Time horizons: immediate (days–weeks) for testing and staffing demand spikes, short-term (weeks–months) for vaccine uptake and hospital margins, long-term (quarters) likely mean reversion to seasonal norm unless mutation occurs. Key hidden dependency: public messaging (CDC/FDA/HHS) and media-driven behavior swings can move demand sharply; monitor 7–14 day hospitalization growth >10% as a trigger.

Trade implications: Favor short-dated tactical longs in diagnostics (ABT, QDEL) and staffing (AMN) for 4–12 week windows; selectively long PFE/SNY on dips into Q1 supply reorder announcements with 3–6 month horizon. Pair trade: long ABT / short AAL for 1–2 months. Use options: buy 8–12 week call spreads on ABT (tactically) and 4–8 week put spreads on major airlines to limit downside and cost. Rotate from discretionary into healthcare staples and defensive consumer staples (Kenvue KVUE, JNJ) if hospitalization growth sustains >2 weeks.

Contrarian angles: Consensus may overstate permanent upside to vaccine makers — pricing power is limited and most demand is seasonal; however staffing and diagnostics may be underpriced and have stickier revenue. Historical parallel: 2017–18 H3N2 produced revenue spikes but compressed hospital margins and limited long-term pharma EPS lift; similar outcome likely unless vaccine escape occurs. Unintended consequence: aggressive media/policy could cause temporary flight-to-quality in Treasuries and healthcare equities; watch CDC strain composition updates as a 48–72 hour volatility catalyst.

Key Decisions for Investors

• Establish a 1.5–2.5% tactical long position in Abbott Laboratories (ABT) for 4–12 weeks, adding into any >5% pullback; hedge with an 8–12 week call spread (buy one ATM, sell 10–15% OTM) to cap cost.
• Establish a 1–2% long position in AMN Healthcare (AMN) for 3 months to capture staffing upside; trim if weekly hospitalizations growth falls below +2% for two consecutive weeks.
• Buy a 0.75–1.5% notional 4–8 week put spread on a major airline (e.g., American Airlines AAL) to profit from short-term travel disruption; use strikes 10–20% OTM to control premium.
• Pair trade 1% long ABT vs 0.75% short Delta Air Lines (DAL) for 1–3 months to express diagnostics outperforming travel; close if CDC reports strain severity downgrade or hospitalization growth <+1% wk/wk.
• Monitor three catalysts over next 30 days—CDC weekly strain report, HHS/FDA vaccination guidance, and state-level hospital capacity alerts—and reweight exposures by ±50% if any trigger (e.g., hospitalization increases >10% wk/wk for two weeks or new vaccine guidance reduces pediatric recommendations) occurs.